More studies are required to comprehend the relationship between insulin secretion through gene therapy with other endocrine parameters involved in the pathogenesis of T1D. Ex vivo insulin gene therapy has been limited by the lack of an optimal cell type that can be easily acquired, changed to make insulin, and reimplanted. Here, INS is linked to type 1 diabetes mellitus.